A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph) (NCI)

ICR 201203-0925-003

OMB: 0925-0654

Federal Form Document

Forms and Documents
Document
Name
Status
Form and Instruction
New
Form and Instruction
New
Form and Instruction
New
Supporting Statement B
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supplementary Document
2012-03-09
Supporting Statement A
2012-03-09
ICR Details
0925-0654 201203-0925-003
Historical Active
HHS/NIH
A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph) (NCI)
New collection (Request for a new OMB Control Number)   No
Emergency 03/12/2012
Approved without change 03/12/2012
Retrieve Notice of Action (NOA) 03/10/2012
This emergency ICR is approved for 6 months with the understanding that, in order for continued approval, the standard notice and comment periods will be followed before the end of the 6-months. Chinese language versions of the instruments must also be provided.
  Inventory as of this Action Requested Previously Approved
09/30/2012 6 Months From Approved
8,606 0 0
5,302 0 0
0 0 0

AsiaLymph will confirm and extend previous findings and yield novel insights into the causes of lymphoma in both Asia and in the United States. The major postulated risk factors for evaluation in this study are chemical exposures (i.e., organochlorines, trichloroethylene, and benzene) and genetic susceptibility. Other factors potentially related to lymphoma, such as viral infections, ultraviolet radiation exposure, medical conditions, and other lifestyle factors will also be studied.
This is a request for an emergency clearance of the "AsiaLymph Study" on the grounds that this is essential to the mission of National Cancer Institute (NCI) and that NCI cannot reasonably comply with the normal clearance procedures and this would likely prevent or substantially disrupt the collection of information (5CFR 1320.13). In addition, prevention of the study would cause public harm through the loss of critically needed information to understand and reduce the cancer burden from lymphoid malignancies in the Asian population, the incidence of which has risen in recent decades. The planned start date for AsiaLymph is March 12, 2012.

US Code: 42 USC 411(285a) Name of Law: Public Health Service Act
  
None

Not associated with rulemaking

  77 FR 9665 02/17/2012
Yes

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 8,606 0 0 8,606 0 0
Annual Time Burden (Hours) 5,302 0 0 5,302 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
This is a new information collection.

$909,200
Yes Part B of Supporting Statement
No
No
No
No
Uncollected
Mikia Currie 3014350941

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
03/10/2012


© 2024 OMB.report | Privacy Policy